# name
Pulmonary hypertension in chronic lung disease and hypoxia

# metadata.dc.description.abstract[].value
Pulmonary hypertension (PH) frequently complicates the course of patients with various forms of chronic lung disease (CLD). CLD-associated PH (CLD-PH) is invariably associated with reduced functional ability, impaired quality of life, greater oxygen requirements and an increased risk of mortality. The aetiology of CLD-PH is complex and multifactorial, with differences in the pathogenic sequelae between the diverse forms of CLD. Haemodynamic evaluation of PH severity should be contextualised within the extent of the underlying lung disease, which is best gauged through a combination of physiological and imaging assessment. Who, when, if and how to screen for PH will be addressed in this article, as will the current state of knowledge with regard to the role of treatment with pulmonary vasoactive agents. Although such therapy cannot be endorsed given the current state of findings, future studies in this area are strongly encouraged.

# metadata.dc.relation.ispartof[].value
European Respiratory Journal, 2019, vol. 53, num. 1, p. 1801914

# metadata.dc.rights[].value
cc-by-nc (c)  European Respiratory Society, 2019

# metadata.dc.source[].value
Articles publicats en revistes (Medicina)

# metadata.dc.title[].value
Pulmonary hypertension in chronic lung disease and hypoxia